Buscar
Mostrando ítems 1-7 de 7
Artículo
Cancer nano-immunotherapy: the novel and promising weapon to fight cancer
(Mdpi Ag, 2024)
Cancer is a complex disease that, despite advances in treatment and the greater understanding of the tumor biology until today, continues to be a prevalent and lethal disease. Chemotherapy, radiotherapy, and surgery are ...
Artículo
Leptin, both bad and good actor in cancer
(MDPI, 2021)
Leptin is an important regulator of basal metabolism and food intake, with a pivotal role in obesity. Leptin exerts many different actions on various tissues and systems, including cancer, and is considered as a linkage ...
Artículo
Editorial: Nanoparticle-Mediated Signaling Rewiring and Reprogramming of Immune Responses
(FRONTIERS MEDIA SA, 2022)
Recent advances on the molecular mechanisms that control immune cells are at the core of the development of better immunomodulatory therapies. For example, these mechanisms may enable T cell manipulation interventions ...
Artículo
Defining the Emergence of New Immunotherapy Approaches in Breast Cancer: Role of Myeloid-Derived Suppressor Cells
(Mdpi Ag, 2023)
Breast cancer (BC) continues to be the most diagnosed tumor in women and a very heterogeneous disease both inter- and intratumoral, mainly given by the variety of molecular profiles with different biological and clinical ...
Artículo
Update on in vitro diagnostic tools and treatments for food allergies
(MDPI, 2023)
Food allergy (FA) is an adverse immunological reaction to a specific food that can trigger a wide range of symptoms from mild to life-threatening. This adverse reaction is caused by different immunological mechanisms, ...
Artículo
New horizons in breast cancer: the promise of immunotherapy
(Springer, 2019)
Immunology and immunotherapy of cancer is an expanding feld in oncology, with recent great achievements obtained through the new successful approaches implemented to circumvent immune evasion, which is undoubtedly ...
Artículo
Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study
(MDPI, 2021-10-29)
The PANGEA-Breast trial evaluated a new chemo-immunotherapeutic combination that would synergistically induce long-term clinical benefit in HER2-negative advanced breast cancer patients. Treatment consisted of 21-day cycles ...